Key Points from the Video
- Early & Multi-disciplinary Approach: Immunogenicity is not just a late-stage clinical issue. It must be considered from the very beginning of drug development by a multi-disciplinary team, as the findings will directly inform the final drug label [00:31].
- FDA’s Integrated Summary of Immunogenicity: For a Biologics License Application (BLA), the FDA requires a specific “Integrated Summary of Immunogenicity” with five key sections:
- Critical Role of Clinicians: Clinicians must provide input early on, especially for the risk assessment, by evaluating how patient-related factors (e.g., a compromised vs. intact immune system) could influence the immunogenic response [07:32].
- Strategic Sample Banking: The clinical team should bank patient serum samples for potential future testing. As assay technology improves, re-testing these samples can provide more accurate data for the final submission dossier [09:41].
- Data Integration is Key: The analysis is not just about reporting the presence of anti-drug antibodies (ADAs). The core task is to integrate the ADA results with all other clinical data—pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety—to understand the clinical impact of the immune response [13:49].
- Focus on Specific Safety Events: Both the FDA and EMA require a focused assessment of key safety events potentially linked to immunogenicity, including:
- Use of Samson Criteria: The FDA strongly recommends using the Samson criteria for diagnosing anaphylaxis in clinical trials. This ensures that all potential anaphylactic events are captured systematically, regardless of what the investigator presumes the cause to be [20:57].
- Global Harmonization: For global drug development, both FDA and EMA guidelines must be followed. While there are minor differences, their core requirements are similar, especially the need for an integrated summary of immunogenicity and a final risk management plan [41:28].
